WNS signs new research and analytics services deal with GlaxoSmithKline

Infotech Lead India: BPO major WNS Holdings has signed a new research and analytics services deal with pharmaceutical firm GlaxoSmithKline Services.

As per the extended contract with GlaxoSmithKline Services to deliver high-end research and analytics services, WNS will analyze large amounts of complex data to drive insight-based decisions.

For GlaxoSmithKline, which reported 2 percent drop in revenue to $9.88 billion in Q1 2013, research and analytics services is vital for future growth.

“WNS has been a trusted partner in delivering these high-value analytics solutions to GSK, and we are delighted to announce this contract extension with a recognized leader in the pharmaceutical industry,” said Keshav R. Murugesh, group CEO, WNS Global Services.

WNS enables its clients to make critical business decisions leveraging its research and analytics expertise, deep industry knowledge and robust delivery capabilities.

WNS currently has over 2,000 research and analytics professionals supporting areas such as customer lifecycle analytics, market and business research, strategy and decision support, demand forecasting, customer risk scoring, loss management modeling, and measurement and reporting.

As of March 31, 2013, WNS had 25,520 professionals across 31 delivery centers worldwide including Costa Rica, India, Philippines, Poland, Romania, South Africa, Sri Lanka, United Kingdom and the United States.

The deal is important for the BPO major as WNS is looking at revenue less repair payments of between $460 million and $480 million in FY 2014, up from $436.1 million in fiscal 2013.

 

Ambika K

[email protected]

  • There’s no mention about the size of the BPO deal. Without revealing the financial details, such articles should not get this much attraction..